Targeted therapy for hepatocellular carcinoma

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Nature Reviews Gastroenterology &Hepatology

• Publication date

  2009-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrgastro.2009.86PMID 19488072
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009cited by this paper
• Liver stem cells and hepatocellular carcinoma

  2009cited by this paper
• Molecularly targeted therapy for hepatocellular carcinoma

  2009cited by this paper
• Joint effects of coffee consumption and serum gamma‐glutamyltransferase on the risk of liver cancer

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Moving targets in hepatocellular carcinoma: hepatic progenitor cells as novel targets for tyrosine kinase inhibitors.

  2008cited by this paper
• C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.

  2008cited by this paper
• Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma

  2008cited by this paper
• Molecular therapy for the treatment of hepatocellular carcinoma

  2008cited by this paper
• Design and endpoints of clinical trials in hepatocellular carcinoma.

  2008cited by this paper
• Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma

  2008cited by this paper
• Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large‐volume center

  2008cited by this paper
• Sorafenib in liver cancer--just the beginning.

  2008cited by this paper
• Molecular targeted therapies in hepatocellular carcinoma

  2008cited by this paper
• Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma.

  2008cited by this paper
• K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

  2008cited by this paper
• Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma

  2008cited by this paper
• Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

  2008cited by this paper
• Targeting EGFR in colorectal cancer.

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma - We have won a battle not the war.

  2008cited by this paper
• Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: Analysis of 281 individual data from published series

  2008cited by this paper
• Excellent outcome following down‐staging of hepatocellular carcinoma prior to liver transplantation: An intention‐to‐treat analysis

  2008cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

  2008cited by this paper
• Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

  2008cited by this paper
• Phase II Study of Imatinib in Unresectable Hepatocellular Carcinoma

  2008cited by this paper
• Liver transplantation in patients with hepatocellular carcinoma across Milan criteria

  2008cited by this paper
• The difficult patient.

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.

  2008cited by this paper
• Trends in mortality from hepatocellular carcinoma in Europe, 1980‐2004

  2008cited by this paper
• Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.

  2008cited by this paper
• The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe.

  2008cited by this paper
• Novel advancements in the management of hepatocellular carcinoma in 2008.

  2008cited by this paper
• Modified-dose capecitabine + bevacizumab for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): A phase II, single-arm study

  2007cited by this paper
• The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC)

  2007cited by this paper
• PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

  2007cited by this paper
• 3500 ORAL Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma

  2007cited by this paper
• Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

  2007cited by this paper
• Long‐acting octreotide versus placebo for treatment of advanced HCC: A randomized controlled double‐blind study

  2007cited by this paper
• Tumour suppressors in liver carcinogenesis.

  2007cited by this paper
• Coffee consumption and risk of liver cancer: a meta-analysis.

  2007cited by this paper
• Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC): Results of the phase II study ERGO

  2007cited by this paper
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

  2007cited by this paper
• Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC)

  2007cited by this paper
• A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results

  2007cited by this paper
• Coffee drinking and hepatocellular carcinoma risk: A meta‐analysis

  2007cited by this paper
• Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring

  2007cited by this paper
• Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

  2007cited by this paper
• A phase II study of sunitinib in patients with advanced hepatocellular carcinoma

  2007cited by this paper
• Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

  2007cited by this paper
• Genomics and signaling pathways in hepatocellular carcinoma.

  2007cited by this paper
• Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study

  2007cited by this paper
• Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

  2007cited by this paper
• Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo

  2006cited by this paper
• Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial.

  2006cited by this paper
• Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study.

  2006cited by this paper
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

  2006cited by this paper
• Hepatocellular carcinoma pathogenesis: from genes to environment

  2006cited by this paper
• Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203.

  2006cited by this paper
• Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.

  2006cited by this paper
• Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers

  2006cited by this paper
• New therapies for hepatocellular carcinoma

  2006cited by this paper
• Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?

  2006cited by this paper
• Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.

  2006cited by this paper
• Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma

  2006cited by this paper
• Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.

  2006cited by this paper
• Pamidronate induced anti-proliferative, apoptotic, and anti-migratory effects in hepatocellular carcinoma.

  2006cited by this paper
• Tyrosine kinases as targets for cancer therapy.

  2005cited by this paper
• Management of hepatocellular carcinoma

  2005cited by this paper
• Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96).

  2005cited by this paper
• Hepatocellular carcinoma: molecular pathways and new therapeutic targets.

  2005cited by this paper
• Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis

  2005cited by this paper
• Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

  2005cited by this paper
• Opportunities for targeted therapies in hepatocellular carcinoma.

  2005cited by this paper
• Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma.

  2005cited by this paper
• Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (Pts) with unresectable hepatocellular carcinoma (HCC)

  2005cited by this paper
• AASLD single‐topic research conference on hepatocellular carcinoma: Conference proceedings

  2004cited by this paper
• Telomeres and telomerase: A dual role in hepatocarcinogenesis

  2004cited by this paper
• Alcohol and hepatocellular carcinoma.

  2004cited by this paper
• Cancer: An inflammatory link

  2004cited by this paper
• Primary liver cancer: worldwide incidence and trends.

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Obesity and hepatocellular carcinoma.

  2004cited by this paper
• Environmental factors and risk for hepatocellular carcinoma.

  2004cited by this paper
• Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice.

  2004cited by this paper
• Hepatocellular carcinoma: recent trends in the United States.

  2004cited by this paper
• NF-kappaB functions as a tumour promoter in inflammation-associated cancer.

  2004cited by this paper
• Liver Pathology in Obesity

  2004cited by this paper
• NF-κB functions as a tumour promoter in inflammation-associated cancer

  2004cited by this paper
• Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection.

  2004cited by this paper
• Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms.

  2004cited by this paper
• Diagnosis and staging of hepatocellular carcinoma.

  2004cited by this paper
• Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma.

  2004cited by this paper
• Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance.

  2004cited by this paper
• Focus on hepatocellular carcinoma.

  2004cited by this paper
• An update on the molecular genetics of hepatocellular carcinoma.

  2004cited by this paper
• Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

  2003cited by this paper
• The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An Update

  2003cited by this paper

• Development of the FGFR4-ADC bearing the ferroptosis inducer sulfasalazine for hepatocellular carcinoma

  2025cites this paper
• Predictive Prognostic Model for Hepatocellular Carcinoma Based on Seven Genes Participating in Arachidonic Acid Metabolism

  2024cites this paper
• New thiazolidine-2,4-diones as effective anti-proliferative and anti-VEGFR-2 agents: Design, synthesis, in vitro, docking, MD simulations, DFT, ADMET, and toxicity studies

  2023cites this paper
• Roles of protein tyrosine phosphatases in hepatocellular carcinoma progression (Review)

  2023cites this paper
• Comparison of the efficacy and safety of selective internal radiotherapy and sorafenib alone or combined for hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis

  2023cites this paper
• Conjugated Linoleic Acid Treatment Attenuates Cancerous features in Hepatocellular Carcinoma Cells

  2022cites this paper
• Explore the antiproliferative phytocompounds from ethanolic extracts of Citrus paradisi against liver cancer cell line by chemical analysis using TLC and FT-IR spectroscopy.

  2022cites this paper
• Ginsenoside Rk3 Suppresses Hepatocellular Carcinoma Development through Targeting the Gut-Liver Axis.

  2021cites this paper
• Identification of potential biomarkers for diagnosis of hepatocellular carcinoma

  2021cites this paper
• Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine‐2,4‐dione derivatives as VEGFR‐2 inhibitors

  2021cites this paper
• miR-455 Inhibits the Viability and Invasion by Targeting RAB18 in Hepatocellular Carcinoma

  2021cites this paper
• Development and investigation of thiazolidinedione and pyrazoline compounds as antiangiogenic weapons targeting VEGFR-2.

  2021cites this paper
• Insights into nanotherapeutic strategies as an impending approach for liver cancer treatment.

  2020cites this paper
• 5‐(4‐Methoxybenzylidene)thiazolidine‐2,4‐dione‐derived VEGFR‐2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations

  2020cites this paper
• Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.

  2020cites this paper
• Targeting ROCK1/2 blocks cell division and induces mitotic catastrophe in hepatocellular carcinoma.

  2020cites this paper
• In Vitro Anticancer Potential of Berberis lycium Royle Extracts against Human Hepatocarcinoma (HepG2) Cells

  2020cites this paper
• Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5‐[(4‐chloro/2,4‐dichloro)benzylidene]thiazolidine‐2,4‐dione derivatives as VEGFR‐2 inhibitors

  2020cites this paper
• Cyclodextrin-mediated formation of porous RNA nanospheres and their application in synergistic targeted therapeutics of hepatocellular carcinoma.

  2020cites this paper
• Identification of prognostic and metastasis-related alternative splicing signatures in hepatocellular carcinoma

  2020cites this paper
• Application of Paclitaxel-loaded EGFR Peptide-conjugated Magnetic Polymeric Liposomes for Liver Cancer Therapy

  2020cites this paper
• Phosphorylation of p53 Serine 15 Is a Predictor of Survival for Patients with Hepatocellular Carcinoma

  2019cites this paper
• Enhanced anti-tumor effect of liposomal Fasudil on hepatocellular carcinoma in vitro and in vivo

  2019cites this paper
• The Molecular Chaperone Heat Shock Protein 70 Controls Liver Cancer Initiation and Progression by Regulating Adaptive DNA Damage and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Signaling Pathways

  2019cites this paper
• Potential role of regulatory B cells in Immunological diseases.

  2019cites this paper
• Enhancing the therapeutic effect via elimination of hepatocellular carcinoma stem cells using Bmi1 siRNA delivered by cationic cisplatin nanocapsules.

  2018cites this paper
• In Vivo Phosphoproteome Analysis Reveals Kinome Reprogramming in Hepatocellular Carcinoma*

  2018cites this paper
• Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β‐catenin‐EGFR‐PI3K‐Akt‐mTOR signaling pathway

  2018cites this paper
• Roles of microRNA in liver cancer

  2018cites this paper
• Anti-Cancer Natural Products and Their Bioactive Compounds Inducing ER Stress-Mediated Apoptosis: A Review

  2018cites this paper
• Molecular and cellular oncogenic mechanisms in hepatocellular carcinoma.

  2018cites this paper
• Recent advances in hepatocellular carcinoma therapy.

  2017cites this paper
• Clinical Significance of FANCD2 Gene Expression and its Association with Tumor Progression in Hepatocellular Carcinoma.

  2017cites this paper
• Attenuated RND1 Expression Confers Malignant Phenotype and Predicts Poor Prognosis in Hepatocellular Carcinoma

  2017cites this paper
• Reactive oxygen species dependent phosphorylation of the liver kinase B1/AMP activated protein kinase/ acetyl-CoA carboxylase signaling is critically involved in apoptotic effect of lambertianic acid in hepatocellular carcinoma cells

  2017cites this paper
• Natural Cyclopeptide RA-XII, a New Autophagy Inhibitor, Suppresses Protective Autophagy for Enhancing Apoptosis through AMPK/mTOR/P70S6K Pathways in HepG2 Cells

  2017cites this paper
• Super-SILAC mix coupled with SIM/AIMS assays for targeted verification of phosphopeptides discovered in a large-scale phosphoproteome analysis of hepatocellular carcinoma.

  2017cites this paper
• Complications of Cirrhosis

  2017cites this paper
• Chloroquine sensitizes hepatocellular carcinoma cells to chemotherapy via blocking autophagy and promoting mitochondrial dysfunction.

  2017cites this paper
• Design, synthesis and biological evaluation of novel nitric oxide-donating protoberberine derivatives as antitumor agents.

  2017cites this paper
• Anti-tumor Efficiency of Lipid-coated Cisplatin Nanoparticles Co-loaded with MicroRNA-375

  2016cites this paper
• ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma

  2016cites this paper
• novel inhibitor of FGFR 1 , 2 , 3 , and 4 , inhibits the growth of FGF 19-expressing hepatocellular carcinoma

  2016cites this paper
• Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point‐mutant β‐catenin

  2016cites this paper
• LncRNA CRNDE promotes hepatic carcinoma cell proliferation, migration and invasion by suppressing miR-384.

  2016cites this paper
• Ultrasound-guided intratumoral delivery of doxorubicin from in situ forming implants in a hepatocellular carcinoma model.

  2016cites this paper
• Comment on "combination treatment including targeted therapy for advanced hepatocellular carcinoma".

  2016cites this paper
• Quinazoline derivative compound (11d) as a novel angiogenesis inhibitor inhibiting VEGFR2 and blocking VEGFR2-mediated Akt/mTOR /p70s6k signaling pathway

  2016cites this paper
• Doxorubicin-induced co-assembling nanomedicines with temperature-sensitive acidic polymer and their in-situ-forming hydrogels for intratumoral administration.

  2016cites this paper
• Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer

  2015cites this paper
• Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions

  2015cites this paper
• Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms

  2015cites this paper
• Knockdown of HIF-1α and IL-8 induced apoptosis of hepatocellular carcinoma triggers apoptosis of vascular endothelial cells

  2015cites this paper
• Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.

  2015cites this paper
• Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth

  2015cites this paper
• New Tools for Molecular Therapy of Hepatocellular Carcinoma

  2015cites this paper
• Bioactive compounds of Eriocaulon sieboldianum blocking proliferation and inducing apoptosis of HepG2 cells might be involved in Aurora kinase inhibition.

  2015cites this paper
• Regulation of HIF 1 and IL-8 using RNAi induces Anti-Tumor Effects in Hepatocellular Carcinoma

  2014cites this paper
• Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.

  2014cites this paper
• Aberrant fucosylation of glycosphingolipids in human hepatocellular carcinoma tissues

  2014cites this paper
• Notch1 increases Snail expression under high reactive oxygen species conditions in hepatocellular carcinoma cells

  2014cites this paper
• Licochalcone A induces apoptosis through endoplasmic reticulum stress via a phospholipase Cγ1-, Ca2+-, and reactive oxygen species-dependent pathway in HepG2 human hepatocellular carcinoma cells

  2014cites this paper
• Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents.

  2014cites this paper
• Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts

  2014cites this paper
• Berberine-induced apoptotic and autophagic death of HepG2 cells requires AMPK activation

  2014cites this paper
• Regulatory B cells accelerate hepatocellular carcinoma progression via CD40/CD154 signaling pathway.

  2014cites this paper
• Management of Hepatocellular Carcinoma: Updated Review

  2013cites this paper
• Toll‐like receptor 4 activity protects against hepatocellular tumorigenesis and progression by regulating expression of DNA repair protein Ku70 in mice

  2013cites this paper
• Guttiferone F from the fruit of Garcinia multiflora and its anti-hepatocellular carcinoma activity

  2013cites this paper
• Impact and challenges in assessing tumor purity by next-generation sequencing

  2013cites this paper
• MicroRNA as Cancer Biomarkers and Targets

  2013cites this paper
• 3,3-Dimethyl-1H-pyrrolo[3,2-g]quinolin-2(3H)-one derivatives as novel Raf kinase inhibitors

  2013cites this paper
• Progression of chemically induced hepatocellular carcinoma in mice is suppressed by Caspase-8 through non apoptotic mechanisms

  2013cites this paper
• miR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma.

  2013cites this paper
• Hepatocellular alterations and dysregulation of oncogenic pathways in the liver of transgenic mice overexpressing growth hormone

  2013cites this paper
• SCD1 Expression Is Dispensable for Hepatocarcinogenesis Induced by AKT and Ras Oncogenes in Mice

  2013cites this paper
• Recombinant hHscFv–RC‐RNase protein derived from transgenic tobacco acts as a bifunctional molecular complex against hepatocellular carcinoma

  2012cites this paper
• Patients’ Preferences and Trade Offs for the Treatment of Small Hepatocellular Carcinomas

  2012cites this paper
• Immunobiology of hepatocellular carcinoma

  2012cites this paper
• Das hepatozelluläre Karzinom – von der Immunbiologie zur Immuntherapie

  2012cites this paper
• Preparation of the thienopyridine derivatives loaded liposomes and study on the effect of compound-lipid interaction on release behavior

  2012cites this paper
• Discovery of lamin B1 and vimentin as circulating biomarkers for early hepatocellular carcinoma.

  2012cites this paper
• AKT (v‐akt murine thymoma viral oncogene homolog 1) and N‐Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c‐Myc pathways

  2012cites this paper
• Inhibition of Csn3 expression induces growth arrest and apoptosis of hepatocellular carcinoma cells

  2012cites this paper
• Glyceraldehyde-3-Phosphate Dehydrogenase: A Promising Target for Molecular Therapy in Hepatocellular Carcinoma

  2012cites this paper
• The centrosomal protein tax1 binding protein 2 is a novel tumor suppressor in hepatocellular carcinoma regulated by cyclin‐dependent kinase 2

  2012cites this paper
• Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.

  2012cites this paper
• SKLB70326, a novel small-molecule inhibitor of cell-cycle progression, induces G₀/G₁ phase arrest and apoptosis in human hepatic carcinoma cells.

  2012cites this paper
• Pathogenetic and Prognostic Significance of Inactivation of RASSF Proteins in Human Hepatocellular Carcinoma

  2012cites this paper
• Targeted therapy for liver cancer: updated review in 2012.

  2012cites this paper
• Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma.

  2012cites this paper
• Evaluation of tumor response to systemic therapy in hepatocellular carcinoma.

  2012cites this paper
• Tumoral and angiogenesis factors in hepatocellular carcinoma after locoregional therapy.

  2012cites this paper
• The blood-biliary barrier, tight junctions and human liver diseases.

  2012cites this paper
• The Role of Proline Rich Tyrosine Kinase 2 (Pyk2) on Cisplatin Resistance in Hepatocellular Carcinoma

  2011cites this paper
• Current and Future Methods for Diagnosis of Neoplastic Liver Disease

  2011cites this paper
• Signaling Pathway and Molecular-Targeted Therapy for Hepatocellular Carcinoma

  2011cites this paper
• Evolving molecular mechanism-based strategies for control of hepatocellular carcinoma.

  2011cites this paper
• Clinical and molecular insights into the hepatocellular carcinoma tumour marker des‐γ‐carboxyprothrombin

  2011cites this paper
• Notch1 differentially regulates oncogenesis by wildtype p53 overexpression and p53 mutation in grade III hepatocellular carcinoma

  2011cites this paper